Positive and negative psychotropic effects of levetiracetam (Q46516531)

22 December 2017

title

Positive and negative psychotropic effects of levetiracetam (English)

1 reference

22 December 2017

author name string

C Helmstaedter

1

1 reference

22 December 2017

N E Fritz

2

1 reference

22 December 2017

E Kockelmann

3

1 reference

22 December 2017

N Kosanetzky

4

1 reference

22 December 2017

C E Elger

5

1 reference

22 December 2017

publication date

25 June 2008

1 reference

22 December 2017

published in

Epilepsy Behavior

1 reference

22 December 2017

volume

13

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

page(s)

535-541

1 reference

22 December 2017

Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Levetiracetam as add-on therapy in generalised epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Psychiatric adverse events during levetiracetam therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

The impact of levetiracetam on challenging behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Piracetam therapy does not enhance cognitive functioning in children with down syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Levetiracetam in autistic children: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Levetiracetam for people with mental retardation and refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Behavioral Aspects of Frontal Lobe Epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Factor structure of the Barratt impulsiveness scale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Psychometric properties of an Italian version of the Barratt Impulsiveness Scale-11 (BIS-11) in nonclinical subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Benefit-risk assessment of levetiracetam in the treatment of partial seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

Tolerability of levetiracetam in elderly patients with CNS disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2008.05.012

10.1016/J.YEBEH.2008.05.012

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017